弥漫性大B细胞淋巴瘤基因分型研究进展

弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)在临床特征、基因表达和治疗反应及预后方面均表现出明显异质性.目前,R-CHOP(利妥昔单抗、环磷酰胺、阿霉素、长春新碱、强的松)作为标准治疗方案已不能满足临床需要,而近年的几项基于细胞起源分型进行的R-CHOP+X临床试验均未...

Research progress on genotyping of diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma(DLBCL)shows obvious heterogeneity in clinical features,gene expression,treatment response,and disease prognosis.R-CHOP(rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisone)is a standard treatment regimen for DLBCL that no longer meets clinical needs;indeed,several recent successive clinical trials failed to demonstrate the efficacy of cell-of-origin-based R-CHOP+X therapy.Therefore,in-depth studies on molecular genetic abnormalities associated with DLBCL are urgently needed to develop gene mutation-based classification systems that could serve as a basis for monitoring disease progression and developing therapeutic methods and targeted drugs for this condition.The increasing use of gene detection technology for the molecular-pathological diagnosis of tumors also strongly supports the need for in-depth studies on DLBCL genotyping.Therefore,herein,we review the latest published reports on DLBCL genotype classification systems.